What is the recommended treatment approach for an adult with active rheumatoid arthritis?

Rheumatoid Arthritis Treatment

Start methotrexate immediately upon diagnosis as first-line therapy, aiming for sustained remission or low disease activity, and escalate to biologic or targeted synthetic DMARDs within 3-6 months if the target is not achieved. 1

Initial Treatment Strategy

Immediate DMARD Initiation

• Begin treatment with conventional synthetic DMARDs (csDMARDs) as soon as RA is diagnosed—do not delay, as the disease will not remit spontaneously 1, 2
• Methotrexate is the anchor drug and should be started first in most patients, using effective doses (15-25 mg weekly, oral or subcutaneous) with folic acid supplementation 1, 2
• For patients with low disease activity at presentation, consider starting with hydroxychloroquine or sulfasalazine instead of methotrexate 1
• If methotrexate is contraindicated or not tolerated early, use leflunomide or sulfasalazine as alternatives 1, 3

Subcutaneous Methotrexate Consideration

• Switch to subcutaneous methotrexate if oral formulation causes gastrointestinal intolerance or inadequate absorption 4, 5

Treat-to-Target Approach

Monitoring and Escalation Timeline

• Monitor disease activity every 1-3 months during active disease using validated measures (DAS28, CDAI, or SDAI) 1, 2
• If no improvement by 3 months or target not reached by 6 months, adjust therapy immediately 1, 2
• The therapeutic goal is sustained remission (SDAI ≤3.3) or low disease activity 1, 6

Escalation Strategy After Methotrexate Failure

Patients with Poor Prognostic Factors

Poor prognostic factors include: high RF/ACPA levels (especially at high titers), high disease activity, early joint damage, or failure of 2 csDMARDs 1

For inadequate response to methotrexate monotherapy with poor prognostic factors:

• Add a biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) rather than triple therapy 1
• This recommendation prioritizes rapid onset of benefit and addresses poor tolerability/durability of triple therapy in real-world practice 1
• Options include TNF inhibitors, IL-6 inhibitors, abatacept, rituximab, or JAK inhibitors 1, 4

Patients Without Poor Prognostic Factors

• Consider switching to or adding another csDMARD (leflunomide, sulfasalazine) before escalating to biologics 1
• Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) is an option but has tolerability concerns 1

Glucocorticoid Use: Minimize and Taper

• Use glucocorticoids sparingly and only as short-term bridging therapy while waiting for DMARDs to take effect 1
• Avoid prolonged glucocorticoid use due to increased risks of infection, osteoporosis, and cardiovascular disease 1
• The 2021 ACR guidelines include several recommendations against routine glucocorticoid therapy, reflecting growing evidence of harm 1

Subsequent Treatment Failures

After First bDMARD/tsDMARD Failure

• Switch to a different bDMARD or tsDMARD—can be from the same class or different class 1, 5
• Continue methotrexate as background therapy unless contraindicated 1
• Reassess at 3 months for improvement and 6 months for target achievement 1

JAK Inhibitor Safety Considerations

• In patients over 50 years with cardiovascular risk factors, be aware of potential increased cardiovascular events and malignancy risk with JAK inhibitors (particularly tofacitinib based on FDA safety alert) 1
• Engage in shared decision-making when selecting JAK inhibitors in this population 1

Tapering in Sustained Remission

When to Consider Tapering

• For patients in sustained low disease activity or remission for at least 6 months, consider stepwise dose reduction (not complete discontinuation) of bDMARDs/tsDMARDs 7
• Do not taper if rapid access to rheumatology care or medication reinitiation is challenging 7
• If flare occurs during tapering, promptly reinstitute the prior effective regimen 1

Glucocorticoid Tapering Priority

• Taper and discontinue glucocorticoids first before considering DMARD tapering 1, 6

Special Populations

Preexisting Mild Stable Lung Disease

• Methotrexate can be conditionally initiated in patients with preexisting mild, stable lung disease given its vital role, but monitor closely for toxicity 1

History of Serious Infection

• Evidence is insufficient for specific DMARD recommendations in patients with moderate-to-high disease activity despite csDMARDs who have a history of serious infection—clinical judgment and shared decision-making are essential 1

Malignancy History

• Specific DMARD recommendations cannot be made for patients with active malignancy or recent solid malignancies due to insufficient evidence 1
• Recent data do not support definitive recommendations for or against specific DMARDs in patients with skin cancer history 1

Critical Pitfalls to Avoid

• Do not delay DMARD initiation—every month of untreated active RA increases irreversible joint damage 1, 2
• Do not use inadequate methotrexate doses—many patients receive subtherapeutic doses; push to 20-25 mg weekly if tolerated 2
• Do not continue ineffective therapy beyond 3-6 months—this represents a lost opportunity for disease control 1, 2
• Do not abruptly discontinue DMARDs in remission—taper gradually if desired, with close monitoring 1, 7
• Do not rely on glucocorticoids as maintenance therapy—they are a bridge, not a destination 1